Table I.
Rat body weight (grams).
| Beginning of the study | 21th day | At the end of the study | |||||
|---|---|---|---|---|---|---|---|
| Factor | Median (IQR) | Median (IQR) | Differences from shama | Differences from the beginning of the studyb | Median (IQR) | Differences from the beginning of the studyb | Differences from 21th dayb |
| Groups | |||||||
| Sham (n=9) | 201.0 (4.5) | 235.0 (8.0) | Z=2.677; P=0.007 | 277.0 (9.0) | Z=2.692; P=0.007 | Z=2.680; P=0.007 | |
| PCOS control (n=9) | 202.0 (13.3) | 260.0 (13.0) | Z=3.936; P<0.001 | Z=2.684; P=0.007 | 320.0 (6.0) | Z=2.675; P=0.007 | Z=2.670; P=0.008 |
| Merformin (n=8) | 202.0 (9.5) | 256.0 (10.0) | Z=3.162; P=0.009 | Z=2.668; P=0.008 | 296.5 (4.5) | Z=2.521; P=0.012 | Z=2.524; P=0.012 |
| Metformin + PDE 4i (n=10) | 202.0 (10.0) | 255.5 (9.8) | Z=3.338; P=0.005 | Z=2.805; P=0.005 | 269.5 (10.3) | Z=2.809; P=0.005 | Z=2.818; P=0.005 |
| Comparisons of the groupsc | χ2=0.615; P=0.893 | χ2=18.672; P<0.001 | χ2=30.581; P<0.001 | ||||
a
Bonferroni corrected Mann-Whitney test results.
b
Wilcoxon signed rank test results.
c
Kruskal-Wallis non-parametric analyzing of variance test results. PCOS, polycystic ovary syndrome; PDE4i, phosphodiesterase 4 inhibitor; IQR, interquartile range.